A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

NCT01281592 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumours

Interventions

DRUG: LOR-253 HCl

Sponsor

Aptose Biosciences Inc.